# A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Source: https://onco.cc/trials/nct05669430/  
OnCo record `nct05669430` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in endometrial cancer, head and neck squamous cell carcinoma, melanoma and non-small-cell lung cancer, run by GV20 Therapeutics, now recruiting.

## Summary

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT05669430 by GV20 Therapeutics, with 365 participants planned, started 2023-03-23 and due to reach its primary completion in 2026-12-15. Interventions recorded: GV20-0251 and GV20-0251 and Pembrolizumab [KEYTRUDA®].

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05669430
- Phase: 1/2
- Setting: An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies
- Sponsor: GV20 Therapeutics
- Enrolled: 365

## Sources

- ClinicalTrials.gov NCT05669430: https://clinicaltrials.gov/study/NCT05669430

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct05669430.json